What’s new in the treatment of female pelvic inflammatory disease?

Grzegorz Stachowiak; Tomasz Pertyński

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2010
vol. 9

Send email

Copy url:

abstract:

Review paper

What’s new in the treatment of female pelvic inflammatory disease?

Grzegorz Stachowiak

,

Tomasz Pertyński

Przegląd Menopauzalny 2010; 3: 140–144

Online publish date: 2010/06/16

View full text Get citation

Pelvic inflammatory disease (PID) is a large group of inflammatory polymicrobial illnesses of female genital organs, mostly caused by Chlamydia trachomatis and Neisseria gonorrhoeae. When poorly treated it leads to
some serious distant side effects e.g. impaired fertility. Quinolones play an important role in the treatment of PID, whereas newly introduced moxifloxacin is characterized by high therapeutic efficacy and safety.

keywords:

What’s new in the treatment of female pelvic inflammatory disease?

Grzegorz Stachowiak , Tomasz Pertyński

PID, Chlamydia, inflammation, pelvis minor, moxifloxacin

Grzegorz Stachowiak

,

Tomasz Pertyński